arXiv.itsnick.co

an independent field guide to 23 million papers from arXiv & OpenAlex — not affiliated with arXiv.org

Author

May Mo

11 papers · 1999–2026

1999: 12000: 02001: 02002: 02003: 02004: 02005: 02006: 02007: 02008: 02009: 02010: 02011: 02012: 02013: 02014: 02015: 02016: 02017: 02018: 02019: 12020: 12021: 02022: 02023: 22024: 12025: 22026: 3
1999peak 3 in 20262026

Frequent co-authors

Papers

showing 1–11 of 11 RSS

A case for including spirituality in quality of life measurement in oncology

Marianne J. Brady, Amy H. Peterman, George Fitchett +2 more

Health · Psycho-Oncology · · cited 801× · DOI ↗ · more like this ·

Most of the commonly used quality of life (QOL) instruments in oncology do not include spirituality as a core domain. However, previous research suggests that spirituality might be an important aspect of QOL for cancer patients and that it may, in fact, be especially salient in the context of life-threatening illness. This study used a large (n=1610) and ethnically diverse sample to address three questions relevant to including spirituality in QOL measurement: (1) Does spirituality demonstrate a positive association with QOL?; (2) Is this association unique?; and (3) Is there clinical utility in including spirituality in QOL measurement? Spirituality, as measured by the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being (FACIT-Sp), was found to be associated with QOL to the same degree as physical well-being, a domain unquestioned in its importance to QOL. The…

LEAP: The latent exchangeability prior for borrowing information from historical data

Ethan M. Alt, Xiuya Chang, Xun Jiang +4 more

stat.ME · · cited 9× · arXiv ↗ · more like this ·

It is becoming increasingly popular to elicit informative priors on the basis of historical data. Popular existing priors, including the power prior, commensurate prior, and robust meta-analytic prior provide blanket discounting. Thus, if only a subset of participants in the historical data are exchangeable with the current data, these priors may not be appropriate. In order to combat this issue, propensity score (PS) approaches have been proposed. However, PS approaches are only concerned with the covariate distribution, whereas exchangeability is typically assessed with parameters pertaining to the outcome. In this paper, we introduce the latent exchangeability prior (LEAP), where observations in the historical data are classified into exchangeable and non-exchangeable groups. The LEAP discounts the historical data by identifying the most relevant subjects from the historical data. We…

Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidism

Cynthia Basu, Xiaoye Ma, May Mo +4 more

Statistics and Probability · Pharmaceutical Statistics · · cited 3× · DOI ↗ · more like this ·

In most drug development settings, the regulatory approval process is accompanied by extensive studies performed to understand the drug's pharmacokinetic (PK) and pharmacodynamic (PD) properties. In this article, we attempt to utilize the rich PK/PD data to inform the borrowing of information from adults during pediatric drug development. In pediatric settings, it is especially crucial that we are parsimonious with the patients recruited for experimentation. We illustrate our approaches in the context of clinical trials of cinacalcet for treating secondary hyperparathyroidism in pediatric and adult patients with chronic kidney disease, where we model both parathyroid hormone (efficacy endpoint) and corrected calcium levels (safety endpoint). We use population PK/PD modeling of the cinacalcet data to quantitatively assess the similarity between adults and children, and use this…

A Bayesian Adaptive Umbrella Trial Design with Robust Information Borrowing for Screening Multiple Combination Therapies

Qing Liu, Wenxi Yu, Leiwen Gao +3 more

Statistics and Probability · Statistics in Biopharmaceutical Research · · cited 1× · DOI ↗ · more like this ·

In immuno-oncology, developing combination therapies to overcome resistance to single agent or induce synergistic effects has become a new focus. To accelerate the screening process to identify promising combinations based on objective response rates, we propose a Bayesian adaptive Umbrella Trial design to simultaneously evaluate combinations of an investigational compound with different backbones, where information borrowing across combinations is allowed to increase trial efficiency. A robust borrowing approach is developed to strike a balance between borrowing and not borrowing by accounting for different configurations of homogeneity of treatment effects using Bayesian model averaging. Unlike existing methods that use the response rates to measure the degree of homogeneity by assuming all arms share a common control rate, an advantage of our approach is that it uses relative…

Bayesian Multistate Transition Modeling of Response, Progression, and Death to Elucidate Mechanisms of Survival Benefit in Oncology Trials

Brian Paul Hobbs, Qing Liu, Jianqi Zhang +5 more

Statistics and Probability · JCO oncology advances. · · cited 0× · DOI ↗ · more like this ·

PURPOSE Innovate a novel Bayesian nonparametric approach for clinical trial analysis devised to infer intrinsic survival benefit mechanisms of action (SBMoA) in confirmatory randomized controlled trials (RCTs) with survival end point by comparing 12 intrinsic state transitions between stable disease, early response, progression/recurrence, and death. METHODS The method characterizes patient trajectories through states of stable disease, response, progression, and death using multiplicative transition intensities. Bayesian inference compares observed transition rate differences with benchmark distributions for five SBMoAs (Null, Survival Null, Mediation, Direct, Mixed), yielding posterior predictive probabilities. Performance was evaluated via simulations of phase III trials implemented to compare the accuracy of 12-month interim analyses with final survival analysis results, as well as…

Bayesian network meta-regression for aggregate ordinal outcomes with imprecise categories

Yeongjin Gwon, Ming‐Hui Chen, May Mo +3 more

Statistics and Probability · Journal of Biopharmaceutical Statistics · · cited 0× · DOI ↗ · more like this ·

Comparing emerging treatment options is often challenging because of the sparseness of direct comparisons from head-to-head trials and inconsistencies in outcome measures among published placebo-controlled trials for each treatment. One potential solution is to aggregate the different outcome measures into a single ordinal response variable for consistent evaluation. The ordinal response variable will inevitably contain unknown response categories because they cannot be directly derived from published data in the literature. In this paper, we propose a statistical methodology to overcome such a common but unresolved issue in the context of network meta-regression for aggregate ordinal outcomes. Specifically, we introduce unobserved latent counts and model these counts within a Bayesian framework. The proposed approach includes several existing models as special cases and also allows us…

Improving power in adaptive expansion of biomarker populations in phase 3 clinical trials

Guoqing Diao, Xun Jiang, Donglin Zeng +3 more

Statistics and Probability · Journal of Biopharmaceutical Statistics · · cited 0× · DOI ↗ · more like this ·

With the availability of unprecedented human genomic biomarker data, incorporating such biomarker data has received a lot of attention in phase 3 clinical trials. One particular enrichment design proposed recently in the literature is to recruit more biomarker positive patients in an all-comer study if the treatment effect in the biomarker negative group is less promising than expected. The intuition is to improve the chance of success of the trial since the success rate in the all-comer population may be low. We propose an enrichment design that unifies the existing biomarker adaptive designs for phase 3 clinical trials. In addition, we propose a new test accounting for the correlations among the test statistics based on different groups of patients, including all-comers, biomarker positive patients only, and biomarker negative patients only. We investigate the theoretical properties…

Rejoinder to the discussion on “LEAP: the latent exchangeability prior for borrowing information from historical data”

Ethan M. Alt, Xiuya Chang, Xun Jiang +4 more

Computer Networks and Communications · Biometrics · · cited 0× · DOI ↗ · more like this ·

The discussions of our paper provide insights into the practical considerations of the latent exchangeability prior while also highlighting further extensions. In this rejoinder, we briefly summarize the discussions and provide comments.

Considerations in testing treatment effects on transient event driven health status changes measured by patient reported outcomes

Jingyuan Liu, Jason C. Legg, May Mo +1 more

Statistics and Probability · Statistics in Medicine · · cited 0× · DOI ↗ · more like this ·

Many treatments and drugs are intended to reduce the occurrence of negative events of interest, control the severity of the events, accelerate recovery from the events, or a combination of these effects. While assessing the clinical effect is typically the primary objective of a trial, testing the treatment effect on the health status of patients based on patient reported outcome (PRO) can be a useful component in determining the value of a treatment. Analysis of PROs in this setting, however, face the following challenges: the PRO value immediately after the event occurrence is often not captured, and the effect of the event on health status measured by the PRO is transient as subjects recover over time. Therefore, traditional statistical methods used to assess treatment effects suffer from low power for PROs. In this manuscript, we apply a kernel smoothing technique to estimate…

Improving Power in Randomized Controlled Trials with Time-to-Event Endpoints: A Risk-Free Approach

Junyi Zhou, Qing Liu, May Mo +1 more

stat.ME · · arXiv ↗ · more like this ·

Leveraging external or historical data to improve the efficiency of randomized clinical trials without introducing bias or inflating the Type I error rate remains challenging. Recent work on externally trained prognostic scores, such as PROCOVA for continuous endpoint, has demonstrated a risk-free approach via covariate adjustment. However, extending this paradigm to time-to-event endpoints is nontrivial due to the non-collapsibility of the marginal hazard ratio (HR). In this paper, we address this challenge by proposing a unified framework for incorporating complex, high-dimensional prognostic information learned from external data into the primary analysis of RCTs with time- to-event endpoints, while targeting the marginal hazard ratio. The proposed procedure proceeds in two steps. First, a prognostic score is estimated from external or historical data by regressing martingale…